Mankind Pharma Appoints Healthcare Veteran Anish Bafna as Independent Director
The Indian pharmaceutical company has named the former Healthium Medtech CEO to its board for a five-year term, subject to shareholder approval.
Board Expansion
Mankind Pharma Limited announced the appointment of Anish Vanraj Bafna as an Additional Director in the capacity of Non-Executive Independent Director, effective August 10, 2026, according to a regulatory filing with India's stock exchanges. The appointment, which carries a five-year term, remains subject to shareholder approval through a postal ballot to be circulated in due course (Other Financials filing, 2026-08-10).
The board meeting, which commenced at 3:30 p.m. IST and concluded at 3:45 p.m. IST, made the decision based on recommendations from the company's Nomination and Remuneration Committee (Other Financials filing, 2026-08-10).
Healthcare Industry Veteran
Bafna brings over 30 years of experience in the healthcare and medical devices sector to Mankind Pharma's board. He previously served as Chief Executive Officer and Managing Director of Healthium Medtech Limited for more than eight years, where he drove the company's growth, global expansion, and transformation initiatives. He currently serves as Non-Executive Chairman of Healthium (Other Financials filing, 2026-08-10).
Prior to his leadership role at Healthium, Bafna held senior positions at Baxter International, including President for Japan and Regional Head for Emerging Asia based in Singapore. In the latter role, he oversaw operations across India and Southeast Asia. His career has spanned multiple geographies including Vietnam, Indonesia, Malaysia, Singapore, Japan, and India (Other Financials filing, 2026-08-10).
Bafna holds a Bachelor's Degree in Science (Chemistry) from St. Xavier's, Ahmedabad, and a Post Graduate Diploma in Management from IMDR, Pune (Other Financials filing, 2026-08-10).
Independence Criteria
The company confirmed that Bafna is not related to any promoter, director, or key managerial personnel, and has no inter se relationship with existing directors. He satisfies the independence criteria prescribed under the Companies Act, 2013 and India's listing regulations (Other Financials filing, 2026-08-10).
Mankind Pharma also obtained a declaration pursuant to regulatory circulars confirming that Bafna is not debarred from holding the office of director by the Securities and Exchange Board of India or any other authority (Other Financials filing, 2026-08-10).
Company Context
Mankind Pharma, with a market capitalization of approximately $11 billion, closed at 2,438 rupees per share on August 10. According to MarginX data, the company is expected to report its Q2 2027 results on October 30, 2026.
Recent insider activity tracked by MarginX shows transactions by Sheetal Arora (1,817,070 shares), Arjun Juneja (2,401,128 shares), and Puja Juneja (2,271,336 shares).
The appointment strengthens Mankind Pharma's board with international healthcare expertise as the company continues its operations in India's pharmaceutical market.
This article was generated by MarginX from the Other Financials filing on 2026-08-10. It is not investment advice.